on The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Stake in Avadel Pharmaceuticals
On January 19, 2026, The Vanguard Group, Inc. disclosed its position in Avadel Pharmaceuticals plc. According to Form 8.3 filed with the Irish Takeover Panel, The Vanguard Group holds 5,856,829 ordinary shares of Avadel Pharmaceuticals, representing a 6.01% interest in the company. These shares are categorized as $0.01 ordinary shares.
The position disclosure corresponds to dealings recorded on January 16, 2026. The filing indicates a purchase of 4,005 shares and a sale of 2,618 shares, both at a price of 21.48 USD per share.
No additional agreements, arrangements, or understandings regarding indemnities or options related to these securities have been noted in the disclosure. This announcement provides insight into The Vanguard Group's substantial interest in Avadel Pharmaceuticals.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all The Vanguard Group, Inc. news